CN100422149C - 作为葡糖苷酰鞘氨醇抑制剂的2-(羟基甲基)-3,4,5-三羟基-1-偶苯酰哌啶衍生物 - Google Patents

作为葡糖苷酰鞘氨醇抑制剂的2-(羟基甲基)-3,4,5-三羟基-1-偶苯酰哌啶衍生物 Download PDF

Info

Publication number
CN100422149C
CN100422149C CNB200480016298XA CN200480016298A CN100422149C CN 100422149 C CN100422149 C CN 100422149C CN B200480016298X A CNB200480016298X A CN B200480016298XA CN 200480016298 A CN200480016298 A CN 200480016298A CN 100422149 C CN100422149 C CN 100422149C
Authority
CN
China
Prior art keywords
compound
disease
manufacture
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200480016298XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1805933A (zh
Inventor
迈克·葛雷恩·奥查德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aidu West Pharmaceutical Co Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1805933A publication Critical patent/CN1805933A/zh
Application granted granted Critical
Publication of CN100422149C publication Critical patent/CN100422149C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
CNB200480016298XA 2003-06-13 2004-06-09 作为葡糖苷酰鞘氨醇抑制剂的2-(羟基甲基)-3,4,5-三羟基-1-偶苯酰哌啶衍生物 Expired - Fee Related CN100422149C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0313678.5 2003-06-13
GBGB0313678.5A GB0313678D0 (en) 2003-06-13 2003-06-13 Novel compounds

Publications (2)

Publication Number Publication Date
CN1805933A CN1805933A (zh) 2006-07-19
CN100422149C true CN100422149C (zh) 2008-10-01

Family

ID=27590019

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200480016298XA Expired - Fee Related CN100422149C (zh) 2003-06-13 2004-06-09 作为葡糖苷酰鞘氨醇抑制剂的2-(羟基甲基)-3,4,5-三羟基-1-偶苯酰哌啶衍生物

Country Status (10)

Country Link
US (1) US8071780B2 (https=)
EP (1) EP1636186A1 (https=)
JP (1) JP4780785B2 (https=)
CN (1) CN100422149C (https=)
AU (1) AU2004247469B2 (https=)
BR (1) BRPI0411308A8 (https=)
CA (1) CA2528323C (https=)
GB (1) GB0313678D0 (https=)
IL (1) IL172542A (https=)
WO (1) WO2004111002A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
AU2003246942B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
US7994198B2 (en) * 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CN101888840A (zh) 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
EP3966199B1 (en) 2019-05-10 2026-03-18 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
PH12022552955A1 (en) 2020-05-07 2024-02-26 Alectos Therapeutics Inc Non-lysosomal glucosylceramidase inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055498A1 (en) * 2001-01-12 2002-07-18 Oxford Glycosciences (Uk) Ltd Pharmaceutically active piperidine derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
JPH02306962A (ja) 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JPH0324057A (ja) 1989-06-22 1991-02-01 Tosoh Corp ポリヒドロキシピペリジン類及びその製造法
KR920703056A (ko) 1989-09-07 1992-12-17 아만 히데아키 항 바이러스제
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US5276120A (en) * 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
WO1994025603A1 (de) 1993-05-05 1994-11-10 Boehringer Mannheim Gmbh Cholesterinoxidase aus brevibacterium sterolicum
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5451679A (en) * 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
ATE322900T1 (de) 1996-07-15 2006-04-15 Macrozyme Dnm B V Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
WO1998050359A1 (en) * 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
WO1999001555A1 (en) * 1997-07-03 1999-01-14 The United States Of America Represented By The Secretary, Department Of Health And Human Services Genes for niemann-pick type c disease
PT1030839E (pt) * 1997-11-10 2004-05-31 Searle & Co Utilizacao de iminoacucares para tratar a resistencia a multifarmacos
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
EP1196190B1 (en) * 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
WO2002055489A2 (en) 2000-12-27 2002-07-18 Univ Columbia Pim kinase-related methods
KR20050025144A (ko) * 2002-03-13 2005-03-11 데르 스포엘 아아르노우드 씨 반 수컷 피임에 대한 비호르몬적 접근법
US7994198B2 (en) * 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055498A1 (en) * 2001-01-12 2002-07-18 Oxford Glycosciences (Uk) Ltd Pharmaceutically active piperidine derivatives

Also Published As

Publication number Publication date
CA2528323A1 (en) 2004-12-23
IL172542A (en) 2011-07-31
CA2528323C (en) 2012-07-31
GB0313678D0 (en) 2003-07-16
IL172542A0 (en) 2006-04-10
BRPI0411308A8 (pt) 2017-12-26
AU2004247469A1 (en) 2004-12-23
BRPI0411308A (pt) 2006-07-11
AU2004247469B2 (en) 2009-11-19
CN1805933A (zh) 2006-07-19
JP4780785B2 (ja) 2011-09-28
US8071780B2 (en) 2011-12-06
WO2004111002A1 (en) 2004-12-23
US20070112028A1 (en) 2007-05-17
EP1636186A1 (en) 2006-03-22
JP2006527253A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
KR100879651B1 (ko) 약제학적으로 활성인 피페리딘 유도체
US20080234324A1 (en) Piperidine Derivatives as Gcs Inhibitors
EP1534676B1 (en) Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
CN100422149C (zh) 作为葡糖苷酰鞘氨醇抑制剂的2-(羟基甲基)-3,4,5-三羟基-1-偶苯酰哌啶衍生物
US7994198B2 (en) Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
CN100422150C (zh) 用作葡糖苷酰鞘氨醇合酶(gcs)的2-(羟基甲基)-1-[(4-(戊氧基)苯基)甲基]-3,4,5-哌啶三醇

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171116

Address after: Swiss A Skei Weil

Patentee after: Aidu West Pharmaceutical Co. Ltd.

Address before: Swiss A Schriewer

Patentee before: Actelion Pharmaceuticals Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081001

Termination date: 20180609

CF01 Termination of patent right due to non-payment of annual fee